The Cremins lab investigates the epigenetic mechanisms regulating development and function of the mammalian central nervous system. We map and analyze neuronal epigenomes in three-dimensions using quantitative, genome-wide technologies. We also perturb epigenomes by employing state-of-the art genetic engineering strategies (e.g. CRISPR/Cas9, optoepigenetics). To test our hypotheses, we primarily use embryonic and induced pluripotent stem cell models of neuronal differentiation and disease. Our long-term goal is to discover how genome architecture controls genome function, applying this to study fundamental mechanisms controlling neuronal phenotype and, by extension, the onset and progression of neurodegenerative and neurodevelopmental disease states.

Thomas Gilgenast wins 2nd place for his poster presentation at the Penn
Bioengineering graduate student symposium. Congratulations Thomas!

Jennifer speaks on the lab’s work at Emory University.

Jonathan Beagan successfully defends his thesis work and receives his
PhD. Congratulations Dr. Beagan!

Jon Beagan receives a podium short talk at the Keystone Meeting in
Genome Architecture in Space and Time in Whistler, BC March 2020.

Jennifer presents Jon’s new work exploring the 3D genome in neuronal activation at the 4DN Annual Meeting in Washington D.C.

Our collaborative work with the Blobel lab exploring 3D genome
reconfiguration after mitotic exit is published in Nature
https://www.nature.com/articles/s41586-019-1778-y. Congratulations to
co-authors Kate Titus, Thomas Gilgenast, and Daniel Emerson for their
contributions.

Jennifer presents the lab’s work at the NIH Center of Excellence in Chromatin Biology

logos  

 

Our work is supported by the New York Stem Cell Foundation, the Alfred P. Sloan Foundation, the National Science Foundation, an NIH New Innovator Award through the National Institute of Mental Health and the NIH 4D Nucleome Common Fund Initiative.